# Xvivo Perfusion > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/xvivoperfusion). ## Overview XVIVO Perfusion is a Swedish medical technology company focused on organ preservation, assessment, and recovery for transplantation. Its business spans thoracic and abdominal transplantation technologies, organ recovery services, and digital communication tools used by transplant teams and hospitals across multiple markets. ## Products & services • Lung preservation and perfusion systems • Liver and kidney machine perfusion products • Organ recovery and NRP services • XVIVO FlowHawk transplant communication platform • Disposable consumables and organ-handling solutions - **Thoracic transplantation products** (50%) — Products for lung and heart transplantation, including preservation and machine perfusion systems. - **Abdominal transplantation products** (30%) — Liver and kidney perfusion technologies used to preserve and assess abdominal organs. - **Organ recovery services** (15%) — Clinical recovery services for donor organs, including coordination and transport support. - **Digital workflow solutions** (5%) — Subscription-based communication software for transplant-clinic coordination. - Lung preservation and perfusion systems - Liver and kidney machine perfusion products - Organ recovery and NRP services - XVIVO FlowHawk transplant communication platform - Disposable consumables and organ-handling solutions ## Customers XVIVO sells primarily to transplant centers, hospitals, organ procurement organizations, and clinical teams involved in organ recovery and transplantation. Customers buy its products and services to expand transplant programs, improve organ utilization, and support more efficient coordination across donor and recipient pathways. - **Transplant centers** (primary) — Buy perfusion systems and disposables for lung, liver, kidney, and heart transplantation to improve organ assessment and utilization. - **Hospitals** (primary) — Use organ recovery services and related clinical support to manage donor organs and transplant workflows. - **Organ procurement organizations** (secondary) — Coordinate donor organ recovery and transport, often alongside XVIVO service teams and logistics partners. - **Transplant teams and clinical staff** (secondary) — Use FlowHawk and related workflow tools to coordinate communication across donor, recipient, and recovery teams. - Transplant centers that need organ preservation and perfusion tools - Hospitals that buy organ recovery services and clinical support - Organ procurement organizations coordinating donor organ logistics - Clinicians using FlowHawk for transplant-team communication - Customers seeking to expand transplant volume and organ utilization ## Geography XVIVO is headquartered in Gothenburg, Sweden and operates through subsidiaries in the US, Netherlands, Italy, France, Brazil, Australia, and China. Its revenue base is international, with reported sales concentrated in EMEA for abdominal products and meaningful activity in North and South America for services and selected product lines. - **EMEA** (80%) — Reported for Abdominal Q1 2026 revenue mix - **North and South America** (13%) — Reported for Abdominal Q1 2026 revenue mix; kept aggregated because it spans continents - **APAC** (7%) — Reported for Abdominal Q1 2026 revenue mix - Head office in Gothenburg, Sweden - Subsidiaries in the US, Netherlands, Italy, France, Brazil, Australia, China - Abdominal sales are primarily generated in EMEA - US is important for organ recovery services and future product launches - International footprint supports clinical adoption and regulatory execution ## Strategy XVIVO’s strategy centers on expanding machine perfusion, organ recovery services, and evidence-backed technologies across thoracic and abdominal transplantation. The company is also building a broader commercial platform through new product launches, regulatory approvals, and recurring service and software revenue. - **Broaden machine perfusion adoption** (medium-term) — Installed systems drive recurring disposable sales and deepen customer relationships. - **Expand service solutions in the US** (short-term) — Organ recovery services create recurring revenue and embed XVIVO in transplant workflows. - **Launch heart and liver technologies in key markets** (medium-term) — New indications enlarge the addressable market and diversify the product portfolio. - **Strengthen clinical evidence and regulatory positioning** (medium-term) — Transplant products require strong clinical data and regulatory clearance to scale. - Expand adoption of machine perfusion across more transplant centers - Grow recurring consumables revenue from installed systems - Scale organ recovery services in the US market - Advance heart and liver launches in major regulated markets - Use clinical evidence to support adoption and reimbursement ## Risks XVIVO is exposed to regulatory, clinical, and adoption risk because its products operate in a highly controlled transplant environment and often require clinical evidence before broad commercialization. It also faces currency, financing, and operational risks, along with healthcare-system budget pressure, trade barriers, and the possibility that transplant volumes or new treatment adoption develop more slowly than expected. - **Regulatory delay or failure for new product launches** [high] — Heart and liver technologies require clinical studies and market approvals before broad commercialization. - **Clinical evidence and adoption risk** [high] — Transplant centers require proof of safety and efficacy before changing standard practice. - **Foreign exchange volatility** [medium] — The company reports risk from a stronger SEK versus the USD and EUR. - **Healthcare funding and procurement pressure** [medium] — Customer budgets and medical resource availability affect purchasing and service uptake. - **Product liability and claims risk** [medium] — Medical technology and organ recovery services can create damage and liability exposure. - Regulatory approval risk for new heart and liver products - Clinical trial and evidence risk in highly regulated transplant markets - FX exposure to SEK versus USD and EUR - Healthcare budget pressure can slow purchasing and adoption - Operational and liability risk in organ recovery and medical products ## Accounting The most important accounting judgments are goodwill and capitalized development costs, both of which depend on future commercialization success and impairment testing. Revenue recognition also matters because XVIVO combines product sales, consumables, services, and SaaS subscriptions, while quarterly results can be affected by product mix, machine sales, and the timing of clinical-study revenue. - **Goodwill impairment** — Could materially affect balance sheet and earnings if expected cash flows weaken - **Capitalized development costs** — Affects intangible assets, amortization, and impairment risk - **Revenue recognition across products, services, and SaaS** — Affects quarterly comparability and recurring revenue visibility - **Seasonality and quarter-to-quarter mix** — Can create volatility in reported sales and margins - Goodwill impairment testing can materially affect reported assets and earnings - Capitalized development costs depend on future product success - Mixed revenue streams require different recognition patterns - Service and SaaS contracts affect timing of revenue recognition - Quarterly results can shift with product mix and study-related revenue --- *Last updated: 2026-08-11T04:04:57.176303+00:00*